Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Preferred Stock Liabilities (2020)

Caribou Biosciences (CRBU) has disclosed Preferred Stock Liabilities for 1 consecutive years, with $41.3 million as the latest value for Q4 2020.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $41.3 million in Q4 2020 year-over-year; TTM through Dec 2020 was $41.3 million, a N/A change, with the full-year FY2020 number at $41.3 million, changed N/A from a year prior.
  • Preferred Stock Liabilities was $41.3 million for Q4 2020 at Caribou Biosciences.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $41.3 million in Q4 2020 to a low of $41.3 million in Q4 2020.